Luvadaxistat (TAK-831) is a potent, highly selective, and orally active inhibitor of D-amino acid oxidase (DAAO); it inhibits the oxidative deamination of D-serine by human recombinant DAAO with an IC50 of 14 nM; significantly increases D-serine levels in the brain, plasma, and cerebrospinal fluid of rodents; and has potential for the investigation of schizophrenia.